Participant flow

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma · Source last updated 2026-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles

   id

   FG000

   title

   IPH2101 0.2 mg/kg

2. description

   2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles

   id

   FG001

   title

   IPH2101 2 mg/kg

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         16

      2. group Id

         FG001

         num Subjects

         14

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         16

      2. group Id

         FG001

         num Subjects

         14

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

All patients enrolled were screened in order to verify the inclusion/exclusion criteria. All patients enrolled (30 patients) were analyzed.

recruitment Details

There were 44 patients screened, 14 subjects were not randomized, 12 of whom were screen failures, 30 patients randomized.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice